Mode
Text Size
Log in / Sign up
N/A Completed N=90 Treatment

Dietary Supplements for the Treatment of Angelman Syndrome

Angelman Syndrome · nervous system diseases
Source: ClinicalTrials.gov NCT00348933 ↗
Enrolled (actual)
90
Serious AEs
53.3%
Results posted
Sep 2012
Primary outcomePrimary: Average Change in Functioning in Specific Areas of Development, Including Speech and Communications Skills, Cognitive Abilities and Daily Living Skills — 5.7; 4.7; 5.8; 3.7 units on a scale

Summary

Angelman syndrome (AS) is a complex genetic disorder that affects the nervous system. The purpose of this study is to determine the effectiveness of certain dietary supplements in treating the symptoms of AS.

Outcome Measures

OutcomeResultp-value
PRIMARY
Average Change in Functioning in Specific Areas of Development, Including Speech and Communications Skills, Cognitive Abilities and Daily Living Skills
5.7; 4.7; 5.8; 3.7; 4.7; 2.0
SECONDARY
Change in Levels of Betaine, Creatine, Dimethylglycine, Guanidinoacetate, Homocysteine, and Methionine.
206.9; 83.3; 93.7; 0.11; 2.3; 5.5
SECONDARY
Change in RBC Folate
77

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of AS
  • In stable condition with relatively good control of seizures
  • Willing to comply with treatment, study visit schedule, and study assessments
  • Willing to take oral or G-tube medication
  • Willing to be contacted monthly during the course of the study
  • Parent or guardian willing to provide informed consent

Exclusion Criteria

  • History of liver or kidney disease
  • Currently being treated for a serious acute illness
  • Known hypersensitivity to any of the study drugs
  • Received high-dose folate drug treatment in the 12 months prior to study entry
  • Other significant medical problems, including those involving the liver, kidney, or heart
  • Other comorbidities, genetic disorders, or extreme prematurity; children with autism are not excluded
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00348933). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search